[Synergistic action of lentinan (LNT) with endocrine therapy of breast cancer in rats and humans].
With the aim of clarifying the nature of the synergistic action of LNT with endocrine therapy for mammary tumor, the effect of LNT post-treatment was investigated in rats with DMBA-induced mammary tumors and also in patients with recurrent breast cancer. LNT injection following surgical therapy (Ax + Ox) resulted in a much greater regression of tumor growth than that obtained by surgery alone, but not after medical therapy (Tamoxifen). Image analysis using an immunohistochemical technique revealed that LNT-surgical therapy resulted in marked atrophy of tumors and as well as intense infiltration of T cells, B cells and macrophages into the stroma around the tumor. Blood prolactin level was greatly reduced by LNT injection. A clinical randomized controlled study demonstrated the efficacy and safety of LNT post-treatment with surgical therapy in 33 patients with recurrent breast cancer. The mode of the synergistic action of LNT in combination with endocrine therapy on hormone-dependent tumors was discussed.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000315:Adrenalectomy; D000328:Adult; D000818:Animals; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007912:Lentinan / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000628:therapy*; D008875:Middle Aged; D010052:Ovariectomy; D011134:Polysaccharides / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use*
D011134:Polysaccharides; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D007912:Lentinan; D015127:9,10-Dimethyl-1,2-benzanthracene